Pyxis Oncology shares rise 20.20% intraday as H.C. Wainwright analyst reiterates Buy rating with $5.00 price target.

Pyxis Oncology surged 20.20% intraday following H.C. Wainwright analyst Swayampakula Ramakanth’s reiterated Buy rating, maintaining a $5.00 price target. The analyst cited promising clinical data as the basis for the recommendation, signaling confidence in the company’s therapeutic pipeline and potential regulatory or market progress. The move reflects investor reaction to the upgraded outlook, aligning with the stock’s sharp intraday gains.